CABA — Cabaletta Bio Inc
NASDAQ · Healthcare · Biotechnology
$3.18
-$0.12 (-3.64%)
Cabaletta Bio Inc (CABA) is a biotechnology company listed on NASDAQ. It is led by Steven A. Nichtberger M.D., based in 2929 Arch Street, Philadelphia, PA, United States, 19104, with about 163 employees. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Net income was -$125.9M. CABA currently screens at market cap $143.9M.
Use this CABA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CABA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CABA SEC filings page. Lician reads the product cache first so this HTML stays unique to Cabaletta Bio Inc even when a live quote feed is slow.
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
CABA Key Statistics
Market Cap
$143.91M
Volume
3.80M
Previous Close
$3.25
Day Range
$3.23 – $3.44
EPS
-$2.34
Revenue
$0.00
Net Income
-$115.86M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
163
CABA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$115.86M | -$67.67M | -$52.98M | -$46.29M |
| EPS (Diluted) | -$2.34 | -$1.65 | -$1.81 | -$1.80 |
Total Assets
$185.05M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$163.96M
Operating Cash Flow
-$88.22M
Free Cash Flow
$0.00
Cabaletta Bio Inc Company Information
- Co-Founder, Chairman, CEO & President
- Steven A. Nichtberger M.D.
- Headquarters
- 2929 Arch Street, Philadelphia, PA, United States, 19104
- Website
- www.cabalettabio.com
- Phone
- 267 759 3100
- IPO / Founded
- 2019-10-25
- Sector
- Healthcare
- Industry
- Biotechnology